Avista Capital Partners will acquire Miraca Life Sciences from Miraca Holdings, according to a news release.
Signet Healthcare Partners has announced it has closed its fourth life science fund, Signet Healthcare Partners IV L.P., with $137.2 million of capital commitments.
Warburg Pincus has announced it will invest in Hygenia.
Warburg Pincus, headquartered in New York, is a PE firm that takes a long-term perspective and invest in businesses at all stages of development. It invests healthcare and several other … Continue Reading
Precision BioSciences has announced it has secured $25.6 million in series A financing.
Andrew Alliance has announced the closing of a series B financing round.
iRhythm Technologies has announced it completed raising $17 million in series E financing.
iRhythm, headquartered in San Francisco, is a privately held healthcare information services company that focuses on the management of cardiac arrhythmia information.
The financing round was … Continue Reading
Adaptive Biotechnologies has announced it has completed a series C financing round and completed a newly created series D round of financing with a $105 million investment from Viking Global Investors.
Clarus Ventures has set out to raise $375 million for a new life sciences VC fund, according to multiple reports, including a San Francisco Business Times report.
Akebia Therapeutics has announced (pdf) it has completed a $41 million Series C financing.
Akebia Therapeutics, headquartered in Cincinnati, is a biopharmaceutical company focused on the development of small molecules for the treatment of anemia and vascular disease.
Satter … Continue Reading
Radius Health, Inc., has announced it has completed a new equity financing of $43 million.
In light of the integrity and clinical issues raised by the New England Compounding Centers far-reaching recalls in late 2012, the FDA has urged officials from all 50 states to close regulatory loopholes involving the safety of compounding drugs for … Continue Reading
Versartis, Inc. has announced it has raised $25 million in series C financing led by Aisling Capital.
Versartis, headquartered in Redwood City, Calif., is a biotechnology company developing therapeutics for patients with endocrine disorders.
Referencing S. O’Shea, R. Ricchio’s Law360 article “Mixing Agency Rules May Mean More Taxable Medical Devices" , our McGuireWoods colleagues Melissa Gilmore and Mary DeBartolo recently queried which medical devices are taxable and noted conflicting agency interpretations.
As our colleagues note, … Continue Reading
Just minutes and hours after the US Supreme Court issued its much-anticipated decision regarding the constitutionality of The Patient Protection and Affordable Care Act (PPACA or ACA) on June 28th, commentators in all walks of life scrambled to offer their insights … Continue Reading
Apparently some early participants in the accountable care organization (ACO) program are experiencing problems accessing crucial CMS (Centers for Medicare and Medicaid Services) data.
The acting administrator of CMS has reported to ACO supervisors and others at a conference last … Continue Reading
It is virtually impossible to turn on a TV, radio or podcast . . . or pick up a newspaper or peruse the internet . . . without hearing that the U.S. Supreme Court today began three days of potentially … Continue Reading
Perhaps despite not having the cache of ‘guaranteed-weight-loss’, ‘quit smoking now’ or even a cure-all for cancer, pharmaceuticals for the treatment of rare diseases can be an attractive investment strategy.
Put aside your Sony flat-screen TVs and Blu-Ray players and make way for —flow cytometry. Why is Sony Corporation, a proven global manufacturer in the field of audio, video game, communications, key device and information technology, venturing in the turbulent, … Continue Reading
Pitchbook has reported on a decade of private equity investments in a four-part series focusing on investments, fundraising, exits and fund returns. The highlights are illuminating of the period from 2001 through 2010, with the unsurprising peak in 2007 and … Continue Reading
Since the beginning of 2011, medical diagnostic and monitoring device companies have been performing in an established and even an exceptional manner. To date, these specialized medical device businesses have shown double-digit EPS growth and organic revenue growth in the … Continue Reading
It appears that the glory days of investing in skilled nursing facilities (SNF) are over. In a report from Avalere Health, profits for these facilities are predicted to flatline by 2014, only three short years from now. As a result … Continue Reading
In an acquisition of a healthcare company, the buyer has a host of issues to monitor and track during due diligence, negotiation and documentation of the transaction. The lender will be working through the same issues but will often have … Continue Reading
FDA is clearing up confusion about what types of changes to existing medical devices require new 510(k) submissions by updating its 1997 guidance document, "Deciding When to Submit a 510(k) for a Change to an Existing Device." The … Continue Reading
Join us on November 2 in Deerfield, Illinois for an interactive conference designed for all stakeholders from medical device, durable medical equipment and diagnostic manufacturers and distributors. Speakers will be joining us from Baxter, Sg2, Medtronic, Stryker … Continue Reading